20% Of This Tevogen Bio Holdings Insider's Holdings Were Sold

Looking at Tevogen Bio Holdings Inc.'s (NASDAQ:TVGN ) insider transactions over the last year, we can see that insiders were net sellers. That is, there were more number of shares sold by insiders than there were purchased.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for Tevogen Bio Holdings

Tevogen Bio Holdings Insider Transactions Over The Last Year

In fact, the recent sale by Neal Flomenberg was the biggest sale of Tevogen Bio Holdings shares made by an insider individual in the last twelve months, according to our records. That means that even when the share price was below the current price of US$1.72, an insider wanted to cash in some shares. As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. Please do note, however, that sellers may have a variety of reasons for selling, so we don't know for sure what they think of the stock price. This single sale was just 20% of Neal Flomenberg's stake.

Happily, we note that in the last year insiders paid US$4.5k for 5.61k shares. But insiders sold 1.08m shares worth US$1.7m. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

Tevogen Bio Holdings Insiders Are Selling The Stock

The last quarter saw substantial insider selling of Tevogen Bio Holdings shares. In total, Chief Scientific Officer and Global R&D Lead Neal Flomenberg dumped US$1.7m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

Insider Ownership Of Tevogen Bio Holdings

Many investors like to check how much of a company is owned by insiders. We usually like to see fairly high levels of insider ownership. Tevogen Bio Holdings insiders own 94% of the company, currently worth about US$277m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Do The Tevogen Bio Holdings Insider Transactions Indicate?

An insider hasn't bought Tevogen Bio Holdings stock in the last three months, but there was some selling. Despite some insider buying, the longer term picture doesn't make us feel much more positive. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For instance, we've identified 4 warning signs for Tevogen Bio Holdings (3 don't sit too well with us) you should be aware of.

But note: Tevogen Bio Holdings may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.